Skip Navigation U.S. Department of Health and Human Services www.hhs.gov
Agency for Healthcare Research Quality www.ahrq.gov
Archive print banner
Hospital Surge Model Version 1.3: Description

Public Health Emergency Preparedness

This resource was part of AHRQ's Public Health Emergency Preparedness (PHEP) program, which was discontinued on June 30, 2011, in a realignment of Federal efforts.

This information is for reference purposes only. It was current when produced and may now be outdated. Archive material is no longer maintained, and some links may not work. Persons with disabilities having difficulty accessing this information should contact us at: https://info.ahrq.gov. Let us know the nature of the problem, the Web address of what you want, and your contact information.

Please go to www.ahrq.gov for current information.

Chapter 10. Botulinum Neurotoxin (continued)

10.6 Resources Consumed Per Patient Per Day (continued)

Resource Units Category Lambdaa Child-Moderate Adult-Moderate Child-Severe Adult-Severe
ED ICU Floor ED ICU Floor ED ICU Floor ED ICU Floor
O negative RBC Units Blood Product 0 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
Matched RBC Units Blood Product 0 0.000 0.100 0.000 0.000 0.100 0.000 0.000 0.100 0.000 0.000 0.100 0.000
Cryoprecipitate Units Blood Product 0 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
Platelets Pack Blood Product 0 0.000 0.100 0.000 0.000 0.100 0.000 0.000 0.100 0.000 0.000 0.100 0.000
FFP Units Blood Product 0 0.000 0.250 0.000 0.000 0.250 0.000 0.000 0.250 0.000 0.000 0.250 0.000
Alcohol pads EA (Each) Supplies 0.92 7.800 7.800 3.900 7.800 7.800 3.900 7.800 7.800 3.900 7.800 7.800 3.900
Band-aids EA (Each) Supplies 0.92 1.300 1.300 1.300 1.300 1.300 1.300 1.300 1.300 1.300 1.300 1.300 1.300
ABD bandage pads, sterile EA (Each) Supplies 0.92 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
Basins, bath EA (Each) Supplies 0.92 1.300 1.300 1.300 1.300 1.300 1.300 1.300 1.300 1.300 1.300 1.300 1.300
Bathing supply, prepackaged EA (Each) Supplies 0.92 1.300 1.300 1.300 1.300 1.300 1.300 1.300 1.300 1.300 1.300 1.300 1.300
Bedpans, regular EA (Each) Supplies 0.92 1.300 1.300 1.300 1.300 1.300 1.300 1.300 1.300 1.300 1.300 1.300 1.300
Blankets EA (Each) Supplies 0.92 2.600 2.600 2.600 2.600 2.600 2.600 2.600 2.600 2.600 2.600 2.600 2.600
Diapers, adult EA (Each) Supplies 0.92 0.000 0.000 0.000 0.065 0.260 0.260 0.000 0.000 0.000 0.065 0.260 0.260
Diapers, infant EA (Each) Supplies 0.92 0.260 1.040 1.040 0.000 0.000 0.000 0.260 1.040 1.040 0.000 0.000 0.000
Diapers, pediatric EA (Each) Supplies 0.92 0.244 0.975 0.975 0.000 0.000 0.000 0.244 0.975 0.975 0.000 0.000 0.000
Bed linen EA (Each) Supplies 1 1.300 1.300 1.300 1.300 1.300 1.300 1.300 1.300 1.300 1.300 1.300 1.300
Patient gown EA (Each) Supplies 1 1.300 1.300 1.300 1.300 1.300 1.300 1.300 1.300 1.300 1.300 1.300 1.300
Oseltamivir 75mg po dose EA (Each) Pharmaceutical 0.7 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
Zanamivir 10mg po dose EA (Each) Pharmaceutical 0.7 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
Rimantidine 100mg po dose EA (Each) Pharmaceutical 0.7 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
Ceftriaxone 1g IV dose EA (Each) Pharmaceutical 0.92 0.000 0.500 0.000 0.000 0.500 0.000 0.000 0.500 0.000 0.000 0.500 0.000
Levofloxacin 750mg IV dose EA (Each) Pharmaceutical 0.92 0.000 0.500 0.000 0.000 0.500 0.000 0.000 0.500 0.000 0.000 0.500 0.000
Nafcillin sodium 1g IV dose EA (Each) Pharmaceutical 0.92 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
Vancomycin 1g IV dose EA (Each) Pharmaceutical 0.92 0.000 0.500 0.000 0.000 0.500 0.000 0.000 0.500 0.000 0.000 0.500 0.000
Streptomycin 1g IV/IM dose EA (Each) Pharmaceutical 0.92 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
Doxycycline 100mg IV/PO dose EA (Each) Pharmaceutical 0.7 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
Ciprofloxacin 400mg IV/PO dose EA (Each) Pharmaceutical 0.7 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
Rifampin or other 2nd line anthrax EA (Each) Pharmaceutical 0.7 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
Cefazolin 500mg IV dose EA (Each) Pharmaceutical 0.7 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
Succinylcholine chloride (mg) mg Pharmaceutical 0 0.000 26.650 0.000 0.000 5.850 0.000 0.000 65.000 0.000 0.000 19.500 0.000
Rocuronium (mg) mg Pharmaceutical 0 0.000 18.655 0.000 0.000 3.900 0.000 0.000 45.500 0.000 0.000 13.000 0.000
Fentanyl citrate (mcg) mcg Pharmaceutical 0 0.000 37.310 0.000 0.000 7.800 0.000 0.000 91.000 0.000 0.000 26.000 0.000
Propofol (mg) mg Pharmaceutical 0 0.000 37.310 0.000 0.000 11.700 0.000 0.000 91.000 0.000 0.000 39.000 0.000
Midazolam (mg) mg Pharmaceutical 0 0.000 0.533 0.000 0.000 0.390 0.000 0.000 1.300 0.000 0.000 1.300 0.000
Ketamine (mg) mg Pharmaceutical 0 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
Dopamine HCL (g) g Pharmaceutical 0.9 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
Dobutamine HCl (g) g Pharmaceutical 0.9 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
Norepinephrine (mg) mg Pharmaceutical 0.9 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
LMW heparin, inj. EA (Each) Pharmaceutical 1 0.000 2.000 2.000 0.000 2.000 2.000 0.000 2.000 2.000 0.000 2.000 2.000
Aerosol spacer, pediatric EA (Each) Pharmaceutical 0 1.300 1.300 1.300 0.000 0.000 0.000 1.300 1.300 1.300 0.000 0.000 0.000
Albuterol (mg) EA (Each) Pharmaceutical 0 0.100 3.998 0.400 0.037 1.463 0.146 1.626 9.750 6.503 0.813 4.875 3.252
Ipratropium bromide, inh. (mg) EA (Each) Pharmaceutical 0.9 0.010 0.400 0.040 0.007 0.293 0.029 0.163 0.975 0.650 0.163 0.975 0.650
Antipyretic pediatric (dose) EA (Each) Pharmaceutical 0 1.000 4.000 4.000 0.000 0.000 0.000 1.000 4.000 4.000 0.000 0.000 0.000
Antipyretic adult (tab) EA (Each) Pharmaceutical 0 0.000 0.000 0.000 1.000 4.000 4.000 0.000 0.000 0.000 1.000 4.000 4.000
Antiemetic pediatric suppository EA (Each) Pharmaceutical 0.9 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
Antiemetic adult (tab) EA (Each) Pharmaceutical 0.9 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
GI acid blocker EA (Each) Pharmaceutical 0.9 0.000 2.000 0.000 0.000 2.000 0.000 0.000 2.000 0.000 0.000 2.000 0.000
Methylprednisolone (mg) mg Pharmaceutical 0.9 0.000 18.000 0.000 0.000 18.000 0.000 0.000 18.000 0.000 0.000 18.000 0.000
Botulism immune globulin (BIG-IV dose) EA (Each) Pharmaceutical 0 1.000 0.000 0.000 1.000 0.000 0.000 1.000 0.000 0.000 1.000 0.000 0.000
Botulinum antitoxin trivalent IV/IM dose EA (Each) Pharmaceutical 0 0.000 2.000 0.000 0.000 2.000 0.000 2.000 2.000 0.000 2.000 2.000 0.000
Epinephrine racemic 1:1000 inj (ml) ml Pharmaceutical 0 0.000 0.330 0.000 0.000 0.330 0.000 0.330 0.330 0.000 0.330 0.330 0.000

a Lambda captures the resource requirement decay rate for a resource. Lambda = 1 implies no decay; the patient requires a constant amount of the resource while s/he is hospitalized. Lambda <1 implies that less of the resource is required each day the patient is hospitalized. Go to section 2.2 for details.

10.7 References

1. Arnon SS. Infant botulism. In: Feigin RD, Cherry JD, eds. Textbook of Pediatric Infectious Diseases. 4th ed. Philadelphia: WB Saunders; 1998: 1570-7.

2. Arnon SS, Schechter R, Inglesby TV, et al. for the Working Group on Civilian Biodefense. Botulinum toxin as a biological weapon: medical and public health management. JAMA 2001;285:1059-1070.

3. Arnon SS, Schechter R, Maslanka SE, Jewell NP, Hatheway CL. Human botulism immune globulin for the treatment of infant botulism. N Engl J Med 2006;354:462-71.

4. Barker WH Jr, Weissmann JB, Dowell VR Jr, Gutmann L, Kautter DA. Type B botulism outbreak caused by a commercial food product: West Virginia and Pennsylvania, 1973. JAMA 1977;237(5):456-9.

5. Binder P, Attre O, Boutin JP, et al. Medical management of biological warfare and bioterrorism: place of the immunoprevention and the immunotherapy. Comp Immunol Microbiol Infect Dis 2003;26(5-6):401-21.

6. Black RE, Gunn RA. Hypersensitivity reactions associated with botulinal antitoxin. Am J Med 1980;69(4):567-70.

7. Blake PA, Horwitz MA, Hopkins L, et al. Type A botulism from commercially canned beef stew. South Med J 1977;70(1):5-7.

8. Bradbury-Golas K, Carson L. A 38-year-old man with generalized weakness, bilateral ptosis, stiff neck, and shortness of breath. J Emerg Nurs 2003;29(5):492-4.

9. Case 48-1980: botulism. N Engl J Med 1981;304(13):789-91.

10. Centers for Disease Control and Prevention. Botulism in the United States, 1899-1996. Handbook for Epidemiologists, Clinicians, and Laboratory Workers. Atlanta: Centers for Disease Control and Prevention; 1998.

11. Centers for Disease Control and Prevention. Outbreak of botulism type E associated with eating a beached whale-Western Alaska, July 2002. MMWR Morb Mortal Wkly Rep 2003;52(2):24-6.

12. Cherington M. Clinical spectrum of botulism. Muscle Nerve 1998;21(6):701-10.

13. Cunha BA. Anthrax, tularemia, plague, Ebola or smallpox as agents of bioterrorism: recognition in the emergency room. Clin Microbiol Infect 2002;8(8):489-503.

14. Domingo RM, Haller JS, Gruenthal M. Infant botulism: two recent cases and literature review. J Child Neurol 2008;23(11):1336-46.

15. Franz D, Pitt L, Clayton M, Hanes M, Rose K. Efficacy of prophylactic and therapeutic administration of antitoxin for inhalation botulism. In: Dasgupta B, ed. Botulinum and Tetanus Neurotoxins. New York: Plenum Press; 1993. 473-6.

16. Franz DR, Jahrling PB, McClain DJ, et al. Clinical recognition and management of patients exposed to biological warfare agents. Clin Lab Med 2001;21(3):435-73.

17. Gangarosa EJ, Donadio JA, Armstrong RW, Meyer KF, Brachman PS, Dowell VR. Botulism in the United States, 1899-1969. Am J Epidemiol 1971;93(2):93-101.

18. Hatheway CH, Snyder JD, Seals JE, Edell TA, Lewis GE Jr. Antitoxin levels in botulism patients treated with trivalent equine botulism antitoxin to toxin types A, B, and E. J Infect Dis 1984;150(3):407-12.

19. Hibbs RG, Weber JT, Corwin A, et al. Experience with the use of an investigational F(ab')2 heptavalent botulism immune globulin of equine origin during an outbreak of type E botulism in Egypt. Clin Infect Dis 1996;23(2):337-40.

20. Hughes JM, Blumenthal JR, Merson MH, Lombard GL, Dowell VR Jr, Gangarosa EJ. Clinical features of types A and B food-borne botulism. Ann Intern Med 1981;95(4):442-5.

21. Koenig MG, Drutz DJ, Mushlin AI, Schaffner W, Rogers DE. Type B botulism in man. Am J Med 1967;42(2):208-19.

22. Koenig MG, Spickard A, Cardella MA, Rogers DE. Clinical and laboratory observations on type E botulism in man. Medicine (Baltimore) 1964;43:517-45.

23. Lederberg J. Infectious disease and biological weapons: prophylaxis and mitigation. JAMA 1997;278(5):435-6.

24. MacDonald KL, Spengler RF, Hatheway CL, Hargrett NT, Cohen ML. Type A botulism from sauteed onions: clinical and epidemiologic observations. JAMA 1985;253(9):1275-8.

25. Mann JM, Martin S, Hoffman R, Marrazzo S. Patient recovery from type A botulism: morbidity assessment following a large outbreak. Am J Public Health 1981;71:266-269.

26. Maselli RA, Bakshi N. American Association of Electrodiagnostic Medicine Case Report 16: botulism. Muscle Nerve 2000;23(7):1137-44.

27. Morris JG. Current trends in therapy of botulism in the United States. In: Lewis GJ, ed. Biomedical Aspects of Botulism. New York: Academic Press; 1981. 317-26.

28. O'Mahony M, Mitchell E, Gilbert RJ, et al. An outbreak of foodborne botulism associated with contaminated hazelnut yoghurt. Epidemiol Infect 1990;104(3):389-95.

29. Park JB, Simpson LL. Inhalational poisoning by botulinum toxin and inhalation vaccination with its heavy-chain component. Infect Immun 2003;71(3):1147-54.

30. Paust JC. Respiratory care in acute botulism: a report of four cases. Anesth Analg 1971;50(6):1003-9.

31. Robinson RF, Nahata MC. Management of botulism. Ann Pharmacother 2003;37(1):127-31.

32. Scully RE, Mark EJ, McNeely WF, Ebeling SH, Phillips LD. Massachusetts General Hospital Case 20-1997: a 74-year-old man with progressive cough, dyspnea, and pleural thickening. N Engl J Med 1997;336(26):1895-903.

33. Seals JE, Snyder JD, Edell TA, et al. Restaurant-associated type A botulism: transmission by potato salad. Am J Epidemiol 1981;113(4):436-44.

34. Shapiro RL, Hatheway C, Becher J, Swerdlow DL. Botulism surveillance and emergency response: a public health strategy for a global challenge. JAMA 1997;278(5):433-5.

35. Shapiro RL, Hatheway C, Swerdlow DL. Botulism in the United States: a clinical and epidemiologic review. Ann Intern Med 1998;129(3):221-8.

36. Squarcione S, Prete A, Vellucci L. Botulism surveillance in Italy: 1992-1996. Eur J Epidemiol 1999;15(10):917-22.

37. St Louis ME, Peck SH, Bowering D, et al. Botulism from chopped garlic: delayed recognition of a major outbreak. Ann Intern Med 1988;108(3):363-8.

38. Tacket CO, Shandera WX, Mann JM, Hargrett NT, Blake PA. Equine antitoxin use and other factors that predict outcome in type A foodborne botulism. Am J Med 1984;76(5):794-8.

39. Terranova W, Breman JG, Locey RP, Speck S. Botulism type B: epidemiologic aspects of an extensive outbreak. Am J Epidemiol 1978;108(2):150-6.

40. Terranova W, Palumbo JN, Breman JG. Ocular findings in botulism type B. JAMA 1979;241(5):475-7.

41. Townes JM, Cieslak PR, Hatheway CL, et al. An outbreak of type A botulism associated with a commercial cheese sauce. Ann Intern Med 1996;125(7):558-63.

42. Tucker JB. National health and medical services response to incidents of chemical and biological terrorism. JAMA 1997;278(5):362-8.

43. Villar RG, Shapiro RL, Busto S, et al. Outbreak of type A botulism and development of a botulism surveillance and antitoxin release system in Argentina. JAMA 1999;281(14):1334-8, 40.

44. Wainwright RB, Heyward WL, Middaugh JP, Hatheway CL, Harpster AP, Bender TR. Food-borne botulism in Alaska, 1947-1985: epidemiology and clinical findings. J Infect Dis 1988;157(6):1158-62.

45. Wilcox P, Andolfatto G, Fairbarn MS, Pardy RL. Long-term follow-up of symptoms, pulmonary function, respiratory muscle strength, and exercise performance after botulism. Am Rev Respir Dis 1989;139(1):157-63.

46. Woodruff BA, Griffin PM, McCroskey LM, et al. Clinical and laboratory comparison of botulism from toxin types A, B, and E in the United States, 1975-1988. J Infect Dis 1992;166(6):1281-6.

Return to Contents
Proceed to Next Section

 

The information on this page is archived and provided for reference purposes only.

 

AHRQ Advancing Excellence in Health Care